Faron, etusivu

releases and publications

Faron Pharmaceuticals Ltd: Appointment of CFO

Regulatory

Faron’s Financial Calendar for 2026

Regulatory

INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT

Regulatory

Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an oral presentation on treatment efficacy

Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Regulatory

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Shareholder announcement Regulatory

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients

Regulatory

Faron Pharmaceuticals Ltd: Registration of New Shares

Regulatory

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Regulatory
PreviousNext
Back to top